Cancer　can　invade　or　spread　to　almost　all　parts　of　the　body.　The　increasing　morbidity　and　high　mortality　of　cancer　create　a　great　demand　for　the　development　of　novel　anticancer　drugs.　Coumarin　derivatives　are　ubiquitous　in　nature　and　can　readily　interact　with　diverse　enzymes　and　receptors　in　cancer　cells　via　weak　bond　interactions;　hence,　coumarin　is　a　highly　privileged　pharmacophore　for　the　development　of　novel　anticancer　agents.　This　review　will　focus　on　the　recent　development　of　coumarin　hybrids　as　potential　anticancer　agents　covering　articles　published　from　2019　to　2020.